Experimental model for the irradiation-mediated abscopal effect and factors influencing this effect.
Abscopal effect
anti-PD1 antibody
irradiated-tumor volume
radiation dose
radiotherapy
tumor-specific CD8+ T cells
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
03
2019
accepted:
26
12
2019
entrez:
21
3
2020
pubmed:
21
3
2020
medline:
21
3
2020
Statut:
epublish
Résumé
Radiotherapy (RT) is the primary treatment for cancer. Ionizing radiation from RT induces tumor damage at the irradiated site, and, although clinically infrequent, may cause regression of tumors distant from the irradiated site-a phenomenon known as the abscopal effect. Recently, the abscopal effect has been related to prolongation of overall survival time in cancer patients, though the factors that influence the abscopal effect are not well understood. The aim of this study is to clarify the factors influencing on abscopal effect. Here, we established a mouse model in which we induced the abscopal effect. We injected MC38 (mouse colon adenocarcinoma) cells subcutaneously into C57BL/6 mice at two sites. Only one tumor was irradiated and the sizes of both tumors were measured over time. The non-irradiated-site tumor showed regression, demonstrating the abscopal effect. This effect was enhanced by an increase in the irradiated-tumor volume and by administration of anti-PD1 antibody. When the abscopal effect was induced by a combination of RT and anti-PD1 antibody, it was also influenced by radiation dose and irradiated-tumor volume. These phenomena were also verified in other cell line, B16F10 cells (mouse melanoma cells). These findings provide further evidence of the mechanism for, and factors that influence, the abscopal effect in RT.
Types de publication
Journal Article
Langues
eng
Pagination
440-453Informations de copyright
AJCR Copyright © 2020.
Déclaration de conflit d'intérêts
None.
Références
Nat Rev Clin Oncol. 2015 Sep;12(9):527-40
pubmed: 26122185
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
Oncoimmunology. 2015 Aug 12;5(2):e1075112
pubmed: 27057444
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
Immunity. 1994 Aug;1(5):343-6
pubmed: 7882166
Cell Physiol Biochem. 2017;43(5):1893-1906
pubmed: 29055949
Clin Cancer Res. 2009 Sep 1;15(17):5379-88
pubmed: 19706802
Nat Rev Cancer. 2007 Dec;7(12):949-60
pubmed: 18034185
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
N Engl J Med. 2001 Aug 30;345(9):638-46
pubmed: 11547717
Nat Immunol. 2001 Mar;2(3):261-8
pubmed: 11224527
Exp Hematol Oncol. 2018 Nov 16;7:28
pubmed: 30473928
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Cancer Lett. 2015 Jan 1;356(1):105-13
pubmed: 24139966
Oncoimmunology. 2014 May 14;3:e28780
pubmed: 25083318
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
Br J Radiol. 1953 May;26(305):234-41
pubmed: 13042090
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
Ann Oncol. 2016 Mar;27(3):409-16
pubmed: 26681673
Breast. 2009 Oct;18 Suppl 3:S103-11
pubmed: 19914528
Transl Oncol. 2012 Dec;5(6):404-7
pubmed: 23323154
N Engl J Med. 2012 Mar 8;366(10):925-31
pubmed: 22397654
Cancer Lett. 2015 Jan 1;356(1):82-90
pubmed: 24125863
Cancer Biother Radiopharm. 2012 Feb;27(1):12-22
pubmed: 22283603
Cancer Res. 2014 Oct 1;74(19):5458-68
pubmed: 25274032
J Exp Med. 2017 Apr 3;214(4):895-904
pubmed: 28302645
Cancer Immunol Res. 2015 Jun;3(6):610-9
pubmed: 25701325